Back to Search
Start Over
Analysts: payers addressing MS market as prices rise
- Source :
- Medical Marketing & Media. September 1, 2016, p20, 1 p.
- Publication Year :
- 2016
-
Abstract
- STARTING IN 2010, the traditional multiple sclerosis market was upended by the introduction of three oral drugs. First came the approval of Gilenya, from Novartis, followed by Sanofi's Aubagio, in [...]
- Subjects :
- Novartis AG -- Forecasts and trends
Sanofi S.A. -- Forecasts and trends
Multiple sclerosis
Drugs -- Prices and rates
Drug approval
Pharmaceutical industry -- Forecasts and trends
Market trend/market analysis
Company pricing policy
Business
Health care industry
Aubagio (Medication) -- Prices and rates
Tecfidera (Medication) -- Prices and rates
Gilenya (Medication) -- Prices and rates
Subjects
Details
- Language :
- English
- ISSN :
- 00257354
- Database :
- Gale General OneFile
- Journal :
- Medical Marketing & Media
- Publication Type :
- Periodical
- Accession number :
- edsgcl.464981141